Targeted Intraoperative Radiotherapy using Intrabeam system for Breast Cancer
TARGIT IORT uses the Intrbeam radiotherapy system and is an elegant approach of partial breast irradiation (PBI) using intraoperative radiotherapy (IORT) for breast cancer.
The TARGIT-A trial compares risk-adapted IORT using the TARGIT technique (Intrabeam radiotherapy) with whole breast external beam radiotherapy
- for patients who are 45 years or older and
- is designed to test if a risk adjusted approach using a single dose of IORT using TARGIT givessimilar results as the usual radiotherapy over several weeks.
- This trial has completed recruitment.
- The first results of the TARGIT-A trial were presented in ASCO 2010 and published in the Lancet in July 2010.
- Updated analysis of local recurrence and first results for survival were published in the Lancet in November 2013
The TARGIT-B trial compares a tumour bed boost with IORT using the TARGIT technique vs. conventional external beam radiotherapy tumour bed boost. This is given in addition to whole breast radiotherapy
- for patients who are younger than 45 years, or have a higher risk of cancer recurrence
- and is designed to test if giving an intraoperative tumour bed boost using TARGIT is superior to the usual externally given tumour bed boost, both in addition to whole breast radiotherapy.
- This trial started recruitment in June 2013
- Please click here to read the details of this trial design
Both these trials are for patients who have a breast conserving surgery i.e., wide local excision, or lumpectomy. Breast cancer patients who need a mastectomy are not currently suitable for IORT using the TARGIT technique.
Recent papers about TARGIT IORT using Intrabeam.
Targeted Intraoperative Radiotherapy (Targit) for early breast cancer